Tang-Min Lin Pill
Diabetes Mellitus, Type 2
Guang'anmen Hospital of China Academy of Chinese Medical SciencesPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 81/ 100
Competitive context
142 Active assets in the Diabetes Mellitus, Type 2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Liraglutide RenJi Hospital | Phase 4 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Cotadutide AstraZeneca | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Tang-Min Lin Pill is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →